| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3228c361daad64af6e4d1179ad94c714 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04 |
| filingDate |
2004-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9569b9bbfea7e93a596576945b0e578
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bed5207375d75e21e9a9153ea01c0526
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8601c4ec5ace6fb27ab88dbf3976b30c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3259cfb83b1a205ce628406bbfbfdcbf |
| publicationDate |
2006-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1716154-A1 |
| titleOfInvention |
Process for the preparation of olanzapine form 1 useful as antipsychotic drug |
| abstract |
This invention provides an improved process for the preparation of Olanzapine Form (I). Olanzapine, which is 2-methyl-4-(4-methyl-l-piperazinyl)-10H-thieno[2,3-b] [1,5] benzodiazapine. More specially, the invention provides insitu improved process for the direct preparation of crystalline form of Olanzapine Form (I). The present invention also provides high pure Olanzapine Form I with single individual impurity less than 0. 1 % by HPLC. |
| priorityDate |
2004-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |